AR059741A1 - Formulaciones farmaceuticas liquidas y semisolidas y procedimientos - Google Patents

Formulaciones farmaceuticas liquidas y semisolidas y procedimientos

Info

Publication number
AR059741A1
AR059741A1 ARP070100902A ARP070100902A AR059741A1 AR 059741 A1 AR059741 A1 AR 059741A1 AR P070100902 A ARP070100902 A AR P070100902A AR P070100902 A ARP070100902 A AR P070100902A AR 059741 A1 AR059741 A1 AR 059741A1
Authority
AR
Argentina
Prior art keywords
liquid
pharmaceutical formulations
procedures
semisolid pharmaceutical
semisolid
Prior art date
Application number
ARP070100902A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR059741A1 publication Critical patent/AR059741A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente está dirigida a formulaciones farmacéuticas líquida o semi-solidas de agentes farmacologicamente activos de la formula (1), que son moduladores del receptor estrogeno, y composiciones farmacéuticas y procedimientos de preparacion de éstas.
ARP070100902A 2006-03-06 2007-03-05 Formulaciones farmaceuticas liquidas y semisolidas y procedimientos AR059741A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77984906P 2006-03-06 2006-03-06

Publications (1)

Publication Number Publication Date
AR059741A1 true AR059741A1 (es) 2008-04-23

Family

ID=38475765

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100902A AR059741A1 (es) 2006-03-06 2007-03-05 Formulaciones farmaceuticas liquidas y semisolidas y procedimientos

Country Status (5)

Country Link
US (1) US20070207201A1 (es)
AR (1) AR059741A1 (es)
PE (1) PE20071019A1 (es)
TW (1) TW200800180A (es)
WO (1) WO2007103869A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080241234A1 (en) * 2006-11-21 2008-10-02 Wyeth Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20090239920A1 (en) * 2006-11-21 2009-09-24 Wyeth Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080175900A1 (en) * 2006-11-21 2008-07-24 Wyeth Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080175901A1 (en) * 2006-11-21 2008-07-24 Wyeth Pharmaceutical formulations of a crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
GB2465746B (en) * 2008-11-21 2011-02-16 Fortune Apex Dev Ltd Pharmaceutical composition for topical application
EP2464230B1 (en) * 2009-08-14 2016-10-05 OPKO Health, Inc. Intravenous formulations of rolapitant
CN113677341A (zh) 2019-02-01 2021-11-19 南卡罗莱纳大学 双环吡啶组合物及其用于癌症治疗的方法
WO2020237014A1 (en) * 2019-05-21 2020-11-26 University Of South Carolina 3-amino-4-(4-(4 (dimethylcarbamoyl) phenyl)-1,4-diazepan-1-yl) thieno [2,3-b] pyridine-2-carboxamide for use in cancer therapy and formulations comprising the same
US20230270714A1 (en) * 2021-12-08 2023-08-31 ATAI Life Sciences AG Salvinorin compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3437599A1 (de) * 1984-10-13 1986-04-17 Dolorgiet GmbH & Co KG, 5205 St Augustin Ibuprofen enthaltende weichgelatinekapseln und verfahren zu ihrer herstellung
US5468502A (en) * 1994-12-20 1995-11-21 American Home Products Corporation Ibuprofen enhancing solvent system
US6878751B1 (en) * 2000-10-19 2005-04-12 Imperial College Of Science Technology And Medicine Administration of resveratrol to treat inflammatory respiratory disorders
FR2818905A1 (fr) * 2000-12-28 2002-07-05 Cll Pharma Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
UA83620C2 (ru) * 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
EP1781628A2 (en) * 2004-08-26 2007-05-09 Wyeth a Corporation of the State of Delaware Prodrug substituted benzoxazoles as estrogenic agents
CN101111229A (zh) * 2004-12-02 2008-01-23 惠氏公司 取代苯并唑类化合物的制剂
EP1819322A2 (en) * 2004-12-02 2007-08-22 Wyeth a Corporation of the State of Delaware Formulations of substituted benzoxazoles
MX2007006564A (es) * 2004-12-02 2007-06-19 Wyeth Corp Formulaciones de benzoxazoles sustituidos.
JP2008533012A (ja) * 2005-03-08 2008-08-21 ワイス ２−（３−フルオロ−４−ヒドロキシフェニル）−７−ビニル−１，３−ベンゾキサゾール−５−オールの結晶形成およびエストロゲンレセプターモジュレーターとしてのその使用
AU2007215131A1 (en) * 2006-02-14 2007-08-23 Wyeth Aqueous pharmaceutical formulations of ERbeta selective ligands

Also Published As

Publication number Publication date
WO2007103869A2 (en) 2007-09-13
WO2007103869A3 (en) 2007-12-06
TW200800180A (en) 2008-01-01
PE20071019A1 (es) 2007-10-29
US20070207201A1 (en) 2007-09-06

Similar Documents

Publication Publication Date Title
AR059741A1 (es) Formulaciones farmaceuticas liquidas y semisolidas y procedimientos
UY30573A1 (es) N-(1-hetaril-piperidin-4-il)-(het)arilamidas como moduladores del receptor ep2
UY30572A1 (es) N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2
CR10243A (es) "bencimidazoles 2-sustituidos como modulares de receptor de androgeno selectivos"
MX355683B (es) Composiciones farmacéuticas de paclitaxel, análogos de paclitaxel o conjugados de paclitaxel, y métodos relacionados de preparación y uso.
MA30718B1 (fr) Derives de pyridin-4-yle en tant qu'agents immunomodulateurs.
NI201100016A (es) Formulaciones farmacéuticas que contienen ligandos de receptores de dopamina.
UY30789A1 (es) Derivados de adenina, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
BR112015010649A2 (pt) moduladores de gpr40 à base de pirrolidina
BRPI0715579A2 (pt) "composto, composição farmacêutica e uso de um composto"
CR20140515A (es) Prolinamida-2-5-oxo fenilmetil-n-sustituidos como receptores antagonistas y sus metodos de uso
ECSP088623A (es) Derivados de azepinoindol como agentes farmacéuticos
GEP20135907B (en) L-(piperidin-4-yl)-pyrazole derivatives as gpr 119 modulators
SV2008002986A (es) Moduladores de indol sulfonamida de receptores de progesterona ref. x-17207
CL2012001366A1 (es) Compuestos derivados de carboxamida n-((2-morfolino-5-ariltiazol-4-il)metil), moduladores de receptores nicotinicos alfa 7; composicion farmaceutica; proceso para prepararla; combinacion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer, demencia, esquizofrenia, enfermedad de parkinson, entre otras.
AR047529A1 (es) Compuestos de quinolina sustituidos
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
ECSP088221A (es) Agonistas adrenoreceptores alfa2c
ATE430744T1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
UA109916C2 (uk) 2-аміно-4-арилтіазольні сполуки як антагоністи trра1
GT200600117A (es) Nuevos compuestos farmaceuticos
DOP2011000134A (es) Lactamas como inhibidores de beta secretasa
CY1113759T1 (el) Ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
CR10060A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas

Legal Events

Date Code Title Description
FB Suspension of granting procedure